CN104415215B - Purposes of the black garlic powder in microbial population of animal intestinal tract is adjusted - Google Patents
Purposes of the black garlic powder in microbial population of animal intestinal tract is adjusted Download PDFInfo
- Publication number
- CN104415215B CN104415215B CN201310391091.1A CN201310391091A CN104415215B CN 104415215 B CN104415215 B CN 104415215B CN 201310391091 A CN201310391091 A CN 201310391091A CN 104415215 B CN104415215 B CN 104415215B
- Authority
- CN
- China
- Prior art keywords
- black garlic
- garlic powder
- animal
- group
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 241000383638 Allium nigrum Species 0.000 title claims abstract description 129
- 229940029982 garlic powder Drugs 0.000 title claims abstract description 111
- 241001465754 Metazoa Species 0.000 title claims abstract description 76
- 210000001035 gastrointestinal tract Anatomy 0.000 title claims abstract description 41
- 230000000813 microbial effect Effects 0.000 title abstract description 26
- 239000003814 drug Substances 0.000 claims abstract description 39
- 229940079593 drug Drugs 0.000 claims abstract description 30
- 235000013305 food Nutrition 0.000 claims abstract description 30
- 238000002360 preparation method Methods 0.000 claims abstract description 22
- 235000010081 allicin Nutrition 0.000 claims description 15
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 8
- 239000002245 particle Substances 0.000 claims description 8
- JDLKFOPOAOFWQN-VIFPVBQESA-N Allicin Natural products C=CCS[S@](=O)CC=C JDLKFOPOAOFWQN-VIFPVBQESA-N 0.000 claims description 6
- JDLKFOPOAOFWQN-UHFFFAOYSA-N allicin Chemical group C=CCSS(=O)CC=C JDLKFOPOAOFWQN-UHFFFAOYSA-N 0.000 claims description 6
- 241000894006 Bacteria Species 0.000 claims description 5
- 230000002550 fecal effect Effects 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 2
- 241000193830 Bacillus <bacterium> Species 0.000 claims 2
- 241000186394 Eubacterium Species 0.000 claims 2
- 241000186660 Lactobacillus Species 0.000 claims 2
- 241000607142 Salmonella Species 0.000 claims 2
- 241000607598 Vibrio Species 0.000 claims 2
- 206010047400 Vibrio infections Diseases 0.000 claims 2
- 229940039696 lactobacillus Drugs 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 32
- 230000000968 intestinal effect Effects 0.000 abstract description 31
- 206010028980 Neoplasm Diseases 0.000 abstract description 26
- 238000000034 method Methods 0.000 abstract description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 20
- 201000010099 disease Diseases 0.000 abstract description 19
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 17
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract description 16
- 206010020772 Hypertension Diseases 0.000 abstract description 16
- 230000036039 immunity Effects 0.000 abstract description 12
- 241000192031 Ruminococcus Species 0.000 abstract description 10
- 230000002265 prevention Effects 0.000 abstract description 10
- 239000006041 probiotic Substances 0.000 abstract description 10
- 235000018291 probiotics Nutrition 0.000 abstract description 10
- 241000186000 Bifidobacterium Species 0.000 abstract description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 44
- 239000013641 positive control Substances 0.000 description 30
- 210000004369 blood Anatomy 0.000 description 26
- 239000008280 blood Substances 0.000 description 26
- 239000000047 product Substances 0.000 description 26
- 239000000463 material Substances 0.000 description 24
- 238000002474 experimental method Methods 0.000 description 23
- 241000700159 Rattus Species 0.000 description 21
- 239000002994 raw material Substances 0.000 description 17
- 210000002966 serum Anatomy 0.000 description 16
- 239000003925 fat Substances 0.000 description 15
- 235000000346 sugar Nutrition 0.000 description 14
- 210000000952 spleen Anatomy 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 208000008589 Obesity Diseases 0.000 description 11
- 235000020824 obesity Nutrition 0.000 description 11
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 210000001541 thymus gland Anatomy 0.000 description 10
- 239000008103 glucose Substances 0.000 description 9
- 235000012459 muffins Nutrition 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- 108010006464 Hemolysin Proteins Proteins 0.000 description 8
- 230000000259 anti-tumor effect Effects 0.000 description 8
- 239000002775 capsule Substances 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 239000003228 hemolysin Substances 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- 240000002234 Allium sativum Species 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 230000036772 blood pressure Effects 0.000 description 7
- 235000013399 edible fruits Nutrition 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- 235000011194 food seasoning agent Nutrition 0.000 description 7
- 235000004611 garlic Nutrition 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 210000002784 stomach Anatomy 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 230000002218 hypoglycaemic effect Effects 0.000 description 6
- 108010023302 HDL Cholesterol Proteins 0.000 description 5
- 244000223014 Syzygium aromaticum Species 0.000 description 5
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- 239000003995 emulsifying agent Substances 0.000 description 5
- 235000013402 health food Nutrition 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 230000005180 public health Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 229920002307 Dextran Polymers 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 201000005577 familial hyperlipidemia Diseases 0.000 description 4
- 235000013312 flour Nutrition 0.000 description 4
- 230000003345 hyperglycaemic effect Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000000976 ink Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 230000001151 other effect Effects 0.000 description 4
- 230000000291 postprandial effect Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 235000015112 vegetable and seed oil Nutrition 0.000 description 4
- 239000008158 vegetable oil Substances 0.000 description 4
- 108020004465 16S ribosomal RNA Proteins 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 239000009636 Huang Qi Substances 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 235000013601 eggs Nutrition 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 238000005755 formation reaction Methods 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 238000000265 homogenisation Methods 0.000 description 3
- 235000015243 ice cream Nutrition 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 238000002386 leaching Methods 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 230000000242 pagocytic effect Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000007901 soft capsule Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- AUHDWARTFSKSAC-HEIFUQTGSA-N (2S,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)-2-(6-oxo-1H-purin-9-yl)oxolane-2-carboxylic acid Chemical compound [C@]1([C@H](O)[C@H](O)[C@@H](CO)O1)(N1C=NC=2C(O)=NC=NC12)C(=O)O AUHDWARTFSKSAC-HEIFUQTGSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 238000011725 BALB/c mouse Methods 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010018473 Glycosuria Diseases 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- GRSZFWQUAKGDAV-UHFFFAOYSA-N Inosinic acid Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-UHFFFAOYSA-N 0.000 description 2
- 231100000111 LD50 Toxicity 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 241000209140 Triticum Species 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000012154 double-distilled water Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- -1 glidant Substances 0.000 description 2
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 2
- 235000013928 guanylic acid Nutrition 0.000 description 2
- 239000004226 guanylic acid Substances 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 235000013902 inosinic acid Nutrition 0.000 description 2
- 239000004245 inosinic acid Substances 0.000 description 2
- 229940028843 inosinic acid Drugs 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 2
- 235000013923 monosodium glutamate Nutrition 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000031068 symbiosis, encompassing mutualism through parasitism Effects 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 241001112696 Clostridia Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- 108700005443 Microbial Genes Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229920001688 coating polymer Polymers 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- PYGSKMBEVAICCR-UHFFFAOYSA-N hexa-1,5-diene Chemical group C=CCCC=C PYGSKMBEVAICCR-UHFFFAOYSA-N 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
- 230000000055 hyoplipidemic effect Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000003516 hyperlipidaemic effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- FBAFATDZDUQKNH-UHFFFAOYSA-M iron chloride Chemical compound [Cl-].[Fe] FBAFATDZDUQKNH-UHFFFAOYSA-M 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 239000004223 monosodium glutamate Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 238000009928 pasteurization Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- IYDGMDWEHDFVQI-UHFFFAOYSA-N phosphoric acid;trioxotungsten Chemical compound O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.OP(O)(O)=O IYDGMDWEHDFVQI-UHFFFAOYSA-N 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 241001300301 uncultured bacterium Species 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The method of purposes and adjusting microbial population of animal intestinal tract the invention discloses purposes of the black garlic powder in microbial population of animal intestinal tract is adjusted, the purposes of black garlic powder in medicine preparation, drug and food and its in microbial population of animal intestinal tract is adjusted.Inventor has found, black garlic powder can significantly improve the quantity of the probiotics such as Bifidobacterium in animal intestinal tract, Ruminococcus, so as to significantly adjust the intestinal flora of animal, and then its immunity, the diseases such as prevention or treatment diabetes, hypertension, hyperlipidemia or tumour are enhanced by the effect of intestinal flora.
Description
Technical field
The present invention relates to the new applications of black garlic powder, and in particular, to purposes of the black garlic powder in microbial population of animal intestinal tract is adjusted.
More specifically, the purposes the present invention relates to black garlic powder in microbial population of animal intestinal tract is adjusted, the purposes of black garlic powder in medicine preparation, medicine
Object and food and its purposes and the method for adjusting microbial population of animal intestinal tract in microbial population of animal intestinal tract is adjusted.
Background technology
There are a large amount of symbiosis floras, these bacteriums in normal human largely to colonize in the enteron aisle of people, and quantity is more than
1000000000000000, be equivalent to human body cell sum 10 times, microbial gene quantity is about 3,000,000, about mankind's base
Because of more than 100 times of group gene dosage.The gene of such magnanimity can help microorganism to adapt to changeable environment, be formed simultaneously with
The mutualistic symbiosis relationship of human body interwoveness.The completion of the Human Genome Project so that the mankind are more deep to the understanding of oneself,
But the genome for understanding the mankind can not completely hold the health of the mankind, the micropopulation permanently settled down in human body intestinal canal
Influence to human health is extremely far-reaching, small to digestive tract environment, digestive problems, greatly to fat or thin problem, hypertension, glycosuria
Disease, hyperlipidemia, cancer etc., the life and health of the mankind is closely bound up with them, therefore human body intestinal canal microbial genome
It is known as second set of genome of the mankind.
At present, research confirm human body a variety of diseases such as obesity, diabetes, hypertension, hyperlipidemia, cancer all with enteron aisle
Flora is closely related.Intestinal flora fermentation polysaccharides metabolite mainly has short key aliphatic acid（Acetic acid, propionic acid, butyric acid etc.）, gas
（Hydrogen, carbon dioxide, hydrogen sulfide and methane）And ammonia, wherein hydrogen and carbon dioxide is the main component of gas in colon.People
Enteron aisle in vitro study shows that butyric acid can promote intestinal mucosa reparation and its functional rehabilitation, and inhibits the formation of inflammatory cytokine,
And the secretion of the tumor necrosis factor of intestinal epithelial cell can be reduced, plays anti-inflammatory and antitumor action.In addition, it separately grinds
Study carefully report intestinal flora in Bacteroides and（Or）The variation of Clostridia population and bacterium Uncultured bacterium
The appearance of clone nbw1009b01c1 may influence the occurrence and development of Kazak ethnic population hypertension.Different enteron aisles
Flora spectrum can cause a disease, also can be with diseases prevention.
However, the research in terms of adjusting microbial population of animal intestinal tract at present still needs to be goed deep into.
Invention content
The present invention is directed at least solve one of technical problem in the prior art.For this purpose, one object of the present invention
It is to propose a kind of means that can effectively adjust microbial population of animal intestinal tract.
Inventor is the study found that black garlic powder has the function of to adjust microbial population of animal intestinal tract, and then the work for passing through intestinal flora
With and play strengthen immunity, adjust blood pressure and blood lipoid, antitumor and other effects, and without any side effect, can take for a long time.
Wherein, it should be noted that the effective active composition of black garlic powder is allicin (allicin), chemical entitled diallyl three
Sulfide is slightly soluble in water, is dissolved in the organic solvents such as ethyl alcohol, benzene, ether, at this stage and has no that black garlic powder and allicin are being adjusted
Research and report in terms of intestinal flora.
Thus, according to an aspect of the present invention, the present invention provides use of the black garlic powder in microbial population of animal intestinal tract is adjusted
On the way.According to an embodiment of the invention, black garlic powder can significantly improve the number of the probiotics such as Bifidobacterium in animal intestinal tract, Ruminococcus
Amount, so as to significantly adjust the intestinal flora of animal, and then is played strengthen immunity, is subtracted by the effect of intestinal flora
Fertile, hypoglycemic, lowering blood pressure and blood fat, antitumor and other effects.Its intestines can effectively be adjusted to animal administration black garlic powder as a result,
Road flora, so as to enhance its immunity, the diseases such as prevention or treatment obesity, diabetes, hypertension, hyperlipidemia or tumour.
According to an embodiment of the invention, black garlic powder of the invention can be prepared by following steps：Select size equal
Even fresh black garlic, the garlic clove of peeling is cleaned in peeling, and clothing film is gone to the greatest extent, garlic clove to be placed in low-temperature drying equipment, 60 DEG C of items
5~6h of constant temperature under part, until water content is less than 5%；By dried garlic clove screening and removing impurities, crushed with pulverizer until into powder, used
100~230 mesh sieves are up to black garlic powder.
It should be noted that expression way " use of the black garlic powder in microbial population of animal intestinal tract is adjusted used in herein
The animal species of term " animal " meaning on the way " are not particularly limited.According to an embodiment of the invention, which can be to appoint
What has the animal of enteron aisle organ, preferably mammal, and more preferable rat, mouse, people are optimal to choose.In addition, institute herein
The expression way " prevention or treatment " used be primarily referred to as prevention or auxiliary treatment obesity, diabetes, hypertension, hyperlipidemia and
The diseases such as tumour.
According to an embodiment of the invention, taking black garlic powder does not have any side effect, thus the dosage of black garlic powder not by
Especially limitation, as long as can improve the quantity for being administered the probiotics such as Bifidobacterium in animal intestinal tract, Ruminococcus and effectively
Adjust the intestinal flora of animal.Some specific examples according to the present invention, by the black garlic powder with 0.3~1.0mg garlics
The dosage of element/kg, preferably 0.5mg allicin/kg are administered the animal.It is administered bifid bar in animal intestinal tract as a result,
The quantity of the probiotics such as bacterium, Ruminococcus increases significantly, i.e., black garlic powder adjusts the significant effect of microbial population of animal intestinal tract.
According to an embodiment of the invention, the particle size of the black garlic powder is 60~150 μm, is conducive in raw material as a result,
Active ingredient uniformly disperse, convenient for the gastrointestinal tract of the animal absorb.Thus, it is possible to preferably playing it adjusts animal intestine
The effect of road flora, and then effectively prevent or treat the diseases such as obesity, diabetes, hypertension, hyperlipidemia or tumour.
According to another aspect of the present invention, the effect based on above-mentioned black garlic powder in terms of microbial population of animal intestinal tract is adjusted, this
Invention additionally provides the purposes of black garlic powder in medicine preparation, and the drug is used to adjust microbial population of animal intestinal tract.
Said medicine can be used in adjusting microbial population of animal intestinal tract, and then can play enhancing by the effect of intestinal flora and exempt from
Epidemic disease power, weight-reducing, hypoglycemic, lowering blood pressure and blood fat, antitumor and other effects.Thus, according to an embodiment of the invention, the drug
For strengthen immunity, prevention or treatment obesity, diabetes, hypertension, hyperlipidemia or tumour.
According to an embodiment of the invention, it is big to the animal 0.3~1.0mg of administration allicins/kg, preferably 0.5mg daily
Allicin/kg.Thereby, it is possible to significantly improve to be administered the quantity of the probiotics such as Bifidobacterium in animal intestinal tract, Ruminococcus, adjust
The intestinal flora of animal, and then pass through the effect strengthen immunity of intestinal flora, effectively prevention or treatment obesity, diabetes, height
The diseases such as blood pressure, hyperlipidemia or tumour.
According to an embodiment of the invention, the particle size of the black garlic powder is not particularly limited, as long as can be convenient for drug
It is formed and animal stomach absorbs.Some preferred embodiments according to the present invention, the particle size of the black garlic powder for 60~
150 μm, the active ingredient be conducive to as a result, in raw material uniformly disperses, convenient for being absorbed in the gastrointestinal tract of the animal.As a result, can
It is enough preferably to play the effect of its adjusting microbial population of animal intestinal tract, and then effectively prevent or treat obesity, diabetes, hypertension, height
The diseases such as blood fat or tumour.
According to another aspect of the invention, the present invention also provides a kind of drugs.According to an embodiment of the invention, the drug
Comprising：Black garlic powder；And pharmaceutically acceptable excipient.It is surprisingly found by the inventors that drug of the invention can be carried significantly
Height is administered the quantity of the probiotics such as Bifidobacterium in animal intestinal tract, Ruminococcus, adjusts the intestinal flora of animal, and then passes through
The diseases such as the effect of intestinal flora effectively prevention or treatment obesity, diabetes, hypertension, hyperlipidemia or tumour.
According to an embodiment of the invention, the particle size of black garlic powder contained in drug of the invention is not particularly limited,
As long as can be convenient for, drug is formed and animal stomach absorbs.Some preferred embodiments according to the present invention, the black garlic powder
Equal particle size is 60~150 μm, and the active ingredient be conducive to as a result, in raw material uniformly disperses, convenient in the animal
Gastrointestinal tract absorbs.Thereby, it is possible to preferably play it to adjust the effect of microbial population of animal intestinal tract, and then effectively prevent or treat fertilizer
The diseases such as fat, diabetes, hypertension, hyperlipidemia or tumour.
According to an embodiment of the invention, the type of excipient of the invention is not particularly limited, as long as can make drug shape
Into the dosage form being easily administered.Some specific examples according to the present invention, the excipient are selected from adhesive, fill out
Material, film-coating polymer, plasticizer, glidant, disintegrant and lubricant at least one.
According to an embodiment of the invention, the dosage form of drug of the invention is not particularly limited, if can be convenient for
Medicine.Some specific examples according to the present invention, the drug are in selected from capsule, pill, tablet, granule, oral liquid
Body, oral pastes, aerosol and spray at least one form.Some preferred embodiments according to the present invention, it is described
Drug is in the form of capsule.It is easy to be administered as a result,.
According to an embodiment of the invention, the dosage of drug of the invention is not particularly limited, can be in practical application
It is flexibly selected according to the health status of administration object.According to some embodiments of the present invention, the dosage of the drug is 0.3
~1.0mg allicins/kg, preferably 0.5mg allicins/kg.It is administered Bifidobacterium in animal intestinal tract, Ruminococcus etc. as a result,
The quantity of probiotics dramatically increases, and adjusts the significant effect of microbial population of animal intestinal tract.
According to an embodiment of the invention, the drug is used to adjust microbial population of animal intestinal tract.And then the work for passing through intestinal flora
With strengthen immunity, weight-reducing, hypoglycemic, lowering blood pressure and blood fat, antitumor and other effects can be played.Thus, it is according to the present invention
Other embodiments, the drug are used for strengthen immunity, prevention or treatment obesity, diabetes, hypertension, hyperlipidemia or swollen
Knurl.
In accordance with a further aspect of the present invention, the present invention also provides a kind of food.According to an embodiment of the invention, the food
Comprising：Black garlic powder；And acceptable additive in bromatology.According to an embodiment of the invention, food of the invention can be shown
The quantity for improving and being administered the probiotics such as Bifidobacterium in animal intestinal tract, Ruminococcus is write, effectively adjusts the intestinal flora of animal,
And then effectively prevent or treat the diseases such as obesity, diabetes, hypertension, hyperlipidemia or tumour by the effect of intestinal flora.Together
When, food of the invention also has all raw materials derived from naturally, and securely and reliably, raw material sources are easy to get extensively, and preparation process is simple,
Storing and application are safe, low production cost, stable quality, advantage with long preservation period.
It should be noted that herein used in term " food " should broadly understood, can be it is any can quilt
Edible form, i.e., other than conventional food form, food of the invention can also be health products（Also sometimes referred to as " work(
Energy food "）, drink etc..Some specific examples according to the present invention, food of the invention are selected from biscuit, bread, candy, ice
At least one that river in Henan Province leaching, cake, seasoning are wrapped.
According to an embodiment of the invention, the particle size of black garlic powder contained in food of the invention is not particularly limited,
As long as food formation can be convenient for.Some preferred embodiments according to the present invention, the black garlic powder are ground into particle ruler
Very little is 60~150 μm of fine powder, and the active ingredient be conducive to as a result, in raw material uniformly disperses, convenient in the stomach and intestine of the animal
Road absorbs.Thereby, it is possible to preferably play it to adjust the effect of microbial population of animal intestinal tract, and then effectively prevent or treat fat, sugar
Urinate the diseases such as disease, hypertension, hyperlipidemia or tumour.
According to another aspect of the present invention, the present invention also provides foregoing drug or food, are adjusting animal
Purposes in intestinal flora.Inventor has found, the drug or food of the foregoing present invention is administered to animal, can significantly carry
Height is administered the quantity of the probiotics such as Bifidobacterium in animal intestinal tract, Ruminococcus, effectively adjusts the intestinal flora of animal, and then
Effectively prevent or treat the diseases such as obesity, diabetes, hypertension, hyperlipidemia or tumour by the effect of intestinal flora.
It should be noted that term " administration " used in herein should broadly understood, in addition to conventional drug is given
Outside medicine, for food when can be understood as feeding animal or providing the food.
According to another aspect of the invention, the present invention also provides a kind of methods for adjusting microbial population of animal intestinal tract.According to this
The embodiment of invention, this method are to animal administration black garlic powder, foregoing drug or food.It is according to the present invention
Embodiment can be significantly improved using the method for the present invention and be administered the probiotics such as Bifidobacterium in animal intestinal tract, Ruminococcus
Quantity, effectively adjust the intestinal flora of animal, and then by the way that the effect of intestinal flora effectively prevention or treatment be fat, glycosuria
The diseases such as disease, hypertension, hyperlipidemia or tumour.
In addition, according to an embodiment of the invention, the food or drug of black garlic powder and the present invention comprising black garlic powder, enhancing
The effect of animal immunizing power is better than the function and effect of the Radix Astragali of single component, oligofructose, chitosan oligosaccharide or yeast dextran.
It should also be noted that, new application --- the purposes in microbial population of animal intestinal tract is adjusted of the black garlic powder of the present invention,
Exactly the present inventor just has been surprisingly found that by arduous creative work and a large amount of experimental work.
The additional aspect and advantage of the present invention will be set forth in part in the description, and will partly become from the following description
It obtains significantly or is recognized by the practice of the present invention.
Specific embodiment
The embodiment of the present invention is described below in detail.The embodiments described below is exemplary, and is only used for explaining this hair
It is bright, and be not considered as limiting the invention.Particular technique or condition are not specified in embodiment, according to text in the art
Offer described technology or condition（Such as translated with reference to the works such as J. Pehanorm Brookers, Huang Peitang etc.《Molecular Cloning:A Laboratory guide》,
The third edition, Science Press）Or it is carried out according to product description.Reagents or instruments used without specified manufacturer is
Can be with conventional products that are commercially available, such as can purchase from Illumina companies.
Black garlic powder of the present invention is commercially available or is prepared on demand according to existing conventional techniques extraction,
Here do not tire out one by one and state.The preparation method of black garlic powder is described in example 1 below, but is not limitation of the present invention.
Embodiment 1：The preparation of black garlic powder
Raw material：Fresh black garlic
Preparation method：Fresh black garlic of uniform size is selected, is removed the peel, cleans the garlic clove of peeling, and clothing film is gone to the greatest extent, by garlic
Valve is placed in low-temperature drying equipment, 5~6h of constant temperature under the conditions of 60 DEG C, until water content is less than 5%；The screening of dried garlic clove is removed
It is miscellaneous, it is crushed with pulverizer until into powder, with 100~230 mesh sieves up to black garlic powder.
Embodiment 2：The preparation of black garlic powder capsule
Raw material：Black garlic powder, granular starch
Preparation method：8 parts by weight of black garlic powder, 6 parts by weight of granular starch are weighed, is processed and crushed using research of super-pine crush equipment,
The black garlic powder that grain diameter is 100 microns, granular starch fine powder are obtained, then content material is placed in by homogeneous into mixing fine powders
In soft capsule pellet press, soft capsule is pressed into according to the filling of existing soft capsule production technology.
Embodiment 3：The preparation that black garlic muffin is done
Raw material：Flour, black garlic powder, sweetener, phosphatide, flavoring agent, sodium bicarbonate, vegetable oil, milk powder, fresh hen egg, water
Preparation method：5 parts by weight black garlic powder, 100 parts by weight flour are uniformly mixed, add in 4 parts by weight sugar, 0.5 weight
Part phosphatide, 1.0 parts by weight refined salt, 0.2 parts by weight sodium bicarbonate, 8 parts by weight vegetable oil, 8 parts by weight milk powder, 2 parts by weight fresh hen eggs
With 20 parts by weight drinking water, after above-mentioned raw materials mixing, dough is made, is put into refrigerator cooling.The dough that will have been cooled down from refrigerator
It takes out, is placed on operation console, the dough sheet of 3mm thickness is rolled into rolling pin, stabbed, be placed on baking tray with lace circle stamp, on
Side brush egg liquid is sent into 180 DEG C of oven about 10min and is baked.
Embodiment 4：The preparation of black garlic powder ice cream
Raw material：Black garlic powder, milk powder, sucrose, dilute cream, plant fat, emulsifier, stabilizer, water
Preparation method：0.5~5 parts by weight Emulsifier is melted into simultaneously mixing with 70 DEG C of hot water in pill tank, is then added in
0.6~1.35 parts by weight black garlic powder, 10~15 parts by weight of sucrose and 0.1~0.5 parts by weight stabilizer of premix continue to stir.When
When water temperature is down to 45 DEG C, 4~8 parts by weight dilute creams and 2~8 parts by weight plant fats are added in, continues to stir, then adds in 0.5
~5 parts by weight Emulsifier and 15~20 parts by weight milk powder, batch mixing is obtained after stirring evenly.Gained batch mixing is sieved through through 80~100 mesh
After filter, keep the temperature 30min at 70~85 DEG C and carry out pasteurization, then carry out homogeneous, level-one homogenization pressure 12 with double-stage homogenization method
10min is kept under~15Mpa, 5min is kept under double-stage homogenization pressure 5Mpa, homogenizing temperature is always maintained at 65~70 DEG C.By homogeneous
Material afterwards is cooled to room temperature, and aging 11 at 0~5 DEG C~for 24 hours；Later in outlet temperature is -6 DEG C to -3 DEG C ice cream maker into
The strong stirring of row, then resulting material placed to 12 at -21 DEG C to -18 DEG C~for 24 hours, obtain black garlic powder ice cream.
Embodiment 5：Black garlic powder facilitates the preparation of toppings packet
Raw material：Salt, black garlic powder, monosodium glutamate, inosinicacid+guanylic acid, essence
Preparation method：By 10 parts by weight black garlic powder, 50 parts by weight salt, 10 parts by weight monosodium glutamates, 0.2 parts by weight inosinicacid+
Guanylic acid, 2 parts by weight essence are uniformly mixed, and black garlic powder, which is made, through dry packing technique facilitates toppings packet.
Embodiment 6：The preparation of black garlic pulverized sugar fruit
It according to the molten sugar of the manufacture craft of candy, filtering, stirs off, black garlic powder is added in when reconciling other additives, is then mixed
It closes, cooling, molding, pack, the candy containing black garlic powder is made.The technique in addition to black garlic powder process is added, do by other processes
Method and general candy（Such as sesame seed candy）Technique is identical.
Embodiment 7：The preparation of black garlic powder baked confectionary
Raw material：Wheat flour, vegetable oil, moisturizer, emulsifier, carbohydrate, black garlic powder
Preparation method：By 30 parts by weight vegetable oil, 1 parts by weight moisturizer, 5 parts by weight Emulsifier, 30 parts by weight of saccharide, 25
Gas is filled with after the mixing of parts by weight black garlic powder, modulates creamy substance, then mixed with 100 parts by weight wheat flours, shape, toast
Obtain cake.
Then, it is done with the black garlic powder, black garlic powder capsule, black garlic muffin that are prepared in Examples 1 to 7, black garlic powder ice river in Henan Province
Leaching, black garlic powder seasoning packet, black garlic pulverized sugar fruit and black garlic powder cake, carry out following test：
Embodiment 8：Rat acute toxicity test
By 6 week old specific-pathogen frees（SPF）SD rats 15 are only divided into 3 groups, every group 5 immediately.By the embodiment of the present invention 3
~7 black garlic powder products being prepared are suspended in 0.5% methocel solution, respectively with 1g/kg weight, 5g/kg weight
Every group of 5 SD rats are once administered orally to the dosage of 10g/kg weight, observe death, clinical symptoms and the body of rat
Change again, and carry out blood test and hematochemical test, in postmortem, any exception of visual inspection thorax abdomen gastrointestinal tissue
Phenomenon.
Experimental result is shown：Black garlic powder product of the present invention does not cause any specific clinical symptoms, changes of weight
Or it is dead, blood test, hematochemical test and postmortem also do not change.As a result, due to until 10g/kg weight dosage not
Any poisoning of rat can be caused to change, can determine whether its median lethal dose（LD50）It is far longer than 10g/kg weight, institute of the present invention
The black garlic powder product stated is rated as safe and non-toxic substance.
Embodiment 9：Black garlic powder, which adjusts human body intestinal canal flora, influences experiment
By black garlic powder product prepared by embodiment 2~6 according to the Ministry of Public Health《Health food is examined and assessment technique specification
（2003）》Adjusting intestinal flora function human experiment experimental evaluation method evaluated.It is specific as follows：
1st, the grouping of test-meal experiment
The grouping situation of test-meal experiment see the table below：
1 test-meal experiment packet table of table
2nd, human experiment experimental method
Subject is randomly divided into 5 groups, every group of 10 people, group result is as follows：Group 1 is normal population, and group 2 is II types sugar
Patient is urinated, group 3 is hyperlipemic patients, and group 4 is hyperglycemic patients, and group 5 is tumor patient.Before subject's test-meal, equal nothing
Bacterium takes subject's excrement, and intestinal flora, the reference as background level are examined in 16S rDNA sequencings.
By the grouping situation of table 1, group 1 takes black garlic powder capsule, group 2 takes black garlic muffin and does, organizes 3 and take black garlic powder ice river in Henan Province
Black garlic powder seasoning packet is taken in leaching, group 4, group 5 takes black garlic pulverized sugar fruit, after 4 weeks, takes subject's excrement, 16S rDNA sequencing inspections
Intestinal flora is tested, is compared with background level, compares the increased multiple of its relative abundance.
3rd, intestinal flora detection method
Fecal sample carries out DNA extractions first, then V3~V5 regions of PCR amplification 16S rDNA are surveyed with 454 platforms
Direction V5- is sequenced in sequence>V3.Each sample initial data is averaged 7795 tag, reads long 400bp or so.Eventually for analysis
Tag numbers average out to 3235, reads long 265bp or so.
Wherein, 16S analyses mainly use mothur softwares（http://www.mothur.org/wiki/Mothur_
manual）, including analyses such as Quality Control, OTU clusters, annotations, and on the basis of data species taxonomy is completed, analyze each species
Relative abundance.
4th, experimental result
The result of the test of the present embodiment is as shown in the table.
The sequencing data abundance comparison of 2 each Pseudomonas of people's intestinal flora of table（It is improved again compared with the background level before test-meal
Number）
Table 2 the experimental results showed that, after the black garlic powder product of the test-meal present invention, normal population, diabetes, hyperglycemia, height
Blood fat, tumor patient intestinal flora obtained different degrees of improvement, black garlic powder product of the invention adjusts enteron aisle as a result,
Flora significant effect.
Embodiment 10：The experiment of black garlic powder strengthen immunity function
According to following steps, research 2 gained black garlic muffin of embodiment does the influence to animal immunizing power：
1st, test material
Experimental animal：BALB/C1 monthly age secondary mouses, half male and half female, 20 ± 2g of weight are in a good state of health, by Wuhan
University Medical College Experimental Animal Center provides, production licence number：SCXK（Hubei Province）2008-0004.Every batch of animal is grouped at random.
The recommended dose that the black garlic muffin of the gained of embodiment 2 is done is the daily 250mg/kgbw of mouse (weight), respectively with
Mouse recommends 0.5 times, 1 times and 2 times as low dose group (125mg/kgbw), middle dose group (250mg/kgbw), high agent
Amount group (500mg/kgbw).
If 4 positive controls,
1 group of positive control is astragalus polyose capsule（Primary raw material：Radix Astragali, oligoisomaltose, the double strange medicine company stocks in the Inner Mongol
Part Co., Ltd, the strong word G20040082 of state's food）,
2 groups of positive control is oligofructose oral liquid（Primary raw material：Oligofructose, the limited public affairs of Zhuhai sage protozoa science and technology
Department, the strong word G20050336 of state's food）,
3 groups of positive control is chitosan oligosaccharide capsule（Primary raw material：Chitosan oligosaccharide, Xiamen Blue Bay Science and Technology Co., Ltd., the strong word of state's food
G20110158）,
4 groups of positive control is yeast dextran capsule（Primary raw material：Yeast dextran, Nanjing great Yuan beauty and health cares are limited
Company, the strong word G20110445 of state's food）.
Other main reagent reagents are：Sheep red blood cell (SRBC)（SRBC）, Hank ' s liquid, guinea pig serum, prepared Chinese ink.
The wherein preparation method of Hank ' s liquid：
（1）Store liquid：
NaCl：80.00g KCl：4.00g Na2HPO4·12H2O：1.52g KH2PO4：0.60g, glucose：4.0g
0.4% phenol red liquid：50.00mL, double distilled waters, which add, is settled to 100mL, 115 DEG C of high pressure sterilization 15min, stored frozen.
（2）Working solution：
Double distilled waters of 9 times of volumes, 115 DEG C of high pressure sterilization 15min are added in storage liquid.Face the 5.6% of used time sterilizing
NaHCO3Solution tune pH value (solution is in orange red) to 7.2~7.4.
The preparation of physiological saline：9.00g NaCl are dissolved in the NaCl solution in the bis- distilled waters of 991g up to 0.9%.
2nd, test method
Administration by gavage is taken in experiment.Daily gavage is primary, and blank control group fills equal volume distilled water.Each group mouse is continuously given
After giving tested material 30 days, indices are measured.
The influence of 2.1 pairs of mouse weights, thymus gland/weight, spleen/weight
Neck is taken off after intragastric administration on mice 30d to put to death, and is weighed.Thymus gland and spleen are taken, weighs thymus gland and spleen weight respectively, measures chest
Gland/weight value and spleen/weight value.
2.2 pairs of mouse antibodies cellulations（PFC）Influence
The measure of antibody-producting cell, hemolytic plaque test are that a kind of vitro detection single antibody forms cell（Slurry is thin
Born of the same parents）Method.
Every mouse is immunized in intraperitoneal injection 0.2mL2% (v/v) SRBC.After immune 5d, take mouse spleen that cell concentration is made
It is 5 × 106The splenocyte liquid of a/mL.The solution of l% is made in dissolving agarose, is kept the temperature in 48 DEG C of water-baths, with 2 times of concentration of equivalent
Hank ' s liquid mixing, dispense into small test tube, often pipe 0.5mL.0.05mL10%SRBC and 0.01mL splenocyte suspensions are added in,
Rapid mixing, is poured on slide.Lh is incubated in 37 DEG C of insulating boxs, by complement（Guinea pig serum）It is added in slide slot, then temperature
Educate 1.5h.Count plaque.
The influence of 2.3 pairs of mouse hemolytic antibody nucleus formations（The measure of serum hemolysin）
Every mouse is immunized in intraperitoneal injection 0.2mL2% (v/v) SRBC.After immune 5d, pluck eyeball and take blood in centrifuge tube,
1h is placed, 3000rpm centrifugation 5min collect serum.400 times of normal saline dilution of serum, sequentially adds diluted mouse blood
SRBC0.5mL, the complement of clear 1.0mL, 10% (v/v)（With physiological saline 1：10 dilutions）1.00mL.Separately set with physiological saline generation
The control tube of not increase serum replaced.A DEG C refrigerator 30min stopped reactions, 3000rpm centrifugations 5min are set to 0 after putting 37 DEG C of water-bath 20min.
Supernatant 1.0mL is taken, OD value is measured at spectrophotometer 540nm wavelength.
The influence of 2.4 pairs of mouse carbonic clearances
4 times of prepared Chinese ink, 0.1mL/10g weight are diluted to every mouse tail vein injection.The timing immediately after prepared Chinese ink injection.
Lmin, 10min take blood 0.02mL to add to 2.0mL0.1%Na after prepared Chinese ink is injected2CO3Solution（That is 1g/L）In, in 600nm
OD value is measured at wavelength, with Na2CO3Solution compares.Separately liver and spleen is taken to weigh.Represent small with phagocytic index (α)
The ability of mouse carbonic clearance.
3rd, result of the test
3.1 weight, thymus gland/weight, spleen/weight measurement result
Influence of each tested material to mouse weight, thymus gland/weight ratio and spleen/weight ratio, measurement result such as table
3rd, shown in 4 and 5.
Influence of the 3 each tested material of table to mouse weight
As shown in Table 3, before the tested material of orally administration mouse various dose and after 30d, basic, normal, high 3 dosage groups
Compared with blank control group and positive controls, weight is without significant difference (P>0.05), i.e., to mouse feed 3 it is low, in,
The sample of high dose group and 4 positive controls is on the weight of mouse without influence.
Influence of 4 tested material of table to mouse thymus/weight ratio
| Group | Dosage | Number of animals (only) | Thymus gland/weight ratio (g/g) | P values |
| Blank control group | 0 | 12 | 0.0017±0.0004 | - |
| 1 group of positive control | 1 | 12 | 0.0020±0.0001 | 0.0402 |
| 2 groups of positive control | 0.5mL | 12 | 0.0021±0.0005 | 0.0459 |
| 3 groups of positive control | 1 | 12 | 0.0020±0.0004 | 0.0436 |
| 4 groups of positive control | 1 | 12 | 0.0022±0.0003 | 0.0315 |
| Low dose group | 125mg/kg·bw | 12 | 0.0022±0.0001 | 0.0312 |
| Middle dose group | 250mg/kg·bw | 12 | 0.0023±0.0003 | 0.0213 |
| High dose group | 500mg/kg·bw | 12 | 0.0027±0.0002 | 0.0375 |
As shown in Table 4, after the tested material 30d of orally administration mouse various dose, compared with blank control group, each dosage group
There were significant differences (P ＜ 0.05) for thymus gland/weight ratio, i.e., the sample of 3 dosage groups and 4 positive controls is fed to mouse
Thymus gland/weight ratio of mouse increased.
Influence of 5 tested material of table to mouse spleen/weight ratio
| Group | Dosage | Number of animals (only) | Spleen/weight ratio (g/g) | P values |
| Blank control group | 0 | 12 | 0.0043±0.0006 | - |
| 1 group of positive control | 1 | 12 | 0.0050±0.0008 | 0.0412 |
| 2 groups of positive control | 0.5mL | 12 | 0.0051±0.0006 | 0.0475 |
| 3 groups of positive control | 1 | 12 | 0.0056±0.0005 | 0.0421 |
| 4 groups of positive control | 1 | 12 | 0.0053±0.0006 | 0.0453 |
| Low dose group | 125mg/kg·bw | 12 | 0.0052±0.0004 | 0.0321 |
| Middle dose group | 250mg/kg·bw | 12 | 0.0055±0.0005 | 0.0312 |
| High dose group | 500mg/kg·bw | 12 | 0.0057±0.0005 | 0.0418 |
As shown in Table 5, after the tested material 30d of orally administration mouse various dose, compared with blank control group, each dosage group
There were significant differences (P ＜ 0.05) for spleen/weight ratio, i.e., the sample of 3 dosage groups and 4 positive controls is fed to mouse
Spleen/weight ratio of mouse increased.
3.2 antibody-producting cell（PFC）Measurement result
Antibody-producting cell（PFC）Testing result is as shown in table 6.
Influence of 6 tested material of table to mouse antibodies cellulation number
As shown in Table 6, after the tested material 30d of orally administration mouse various dose, compared with blank control group, positive control
There were significant differences (P ＜ 0.05) for 1 group and low, middle dose group PFC quantity, illustrates high dose group and 3 positive controls
On mouse PFC without influence, and 1 group of positive control, low dose group, middle dose group have a significant impact mouse PFC.
The measurement result of 3.3 serum hemolysins
The measurement result of serum hemolysin is as shown in table 7.
Influence of 7 tested material of table to mice serum hemolysin
| Group | Dosage | Number of animals (only) | HC50 | P values |
| Blank control group | 0 | 12 | 115±24 | - |
| 1 group of positive control | 1 | 12 | 137±32 | 0.1758 |
| 2 groups of positive control | 0.5mL | 12 | 141±29 | 0.3256 |
| 3 groups of positive control | 1 | 12 | 135±17 | 0.0231 |
| 4 groups of positive control | 1 | 12 | 132±18 | 0.1589 |
| Low dose group | 125mg/kg·bw | 12 | 160±21 | 0.0056 |
| Middle dose group | 250mg/kg·bw | 12 | 164±18 | 0.0089 |
| High dose group | 500mg/kg·bw | 12 | 141±23 | 0.0756 |
As shown in Table 7, after the tested material 30d of orally administration mouse various dose, compared with blank control group, low dosage
The HC of group, middle dose group50There are pole significant difference (P ＜ 0.01), the HC that 3 groups of positive control50There were significant differences (P ＜ 0.05),
Illustrate low dose group and middle dose group of the present invention, can pole significantly increase mice serum hemolysin HC50, it is positive
Mice serum hemolysin HC can be significantly improved by compareing 3 groups50, and 1 group of positive control, 2 groups of positive control, 4 groups of positive control, height
Dosage group is to mice serum hemolysin HC50Without influence.
3.4 mouse carbonic clearance experimental results
Mouse carbonic clearance experimental result is as shown in table 8.
Influence of 8 tested material of table to mouse carbonic clearance
As shown in Table 8, after the tested material 30d of orally administration mouse various dose, compared with blank control group, institute of the present invention
Middle dose group, the high dose group stated have pole significant difference (P to mouse macrophage phagocytic activity<0.01), low dose group,
1 group of positive control, 2 groups of positive control have significant difference (P to mouse macrophage phagocytic activity<0.05), remaining group
On mouse carbonic clearance ability without influence.This shows that black garlic powder product of the present invention has enhancing mononuclear macrophage phagocytosis
The effect of function can enhance the non-specific immune function of mouse.
As described in the invention described above black garlic powder product improve immunity function experiment before and after the result shows that, it is each batch small
Mouse weight is dramatically increased without significant difference, thymus gland/weight ratio, spleen/weight ratio.It is examined in mouse antibodies cellulation
It surveys in experiment, serum hemolysin determination experiment and the experiment of mouse carbonic clearance, the significant difference of result.Thus, it is believed that
Black garlic powder product of the present invention has the function of strengthen immunity and effect, and black garlic powder product pair of the present invention
The function and effect for acting on the Radix Astragali better than single component, oligofructose, chitosan oligosaccharide, yeast dextran of strengthen immunity.
Embodiment 11：The hypoglycemic zoopery of black garlic powder
According to the Ministry of Public Health《Health food is examined and assessment technique specification（2003）》Auxiliary hyperglycemic function animal it is real
Evaluation method is tested, embodiment 3 and 5~7 gained black garlic powder product of embodiment are evaluated, it is specific as follows：
1st, test method：Male SD rat 40 is taken, preparing low dose of streptozotocin according to standard method causes diabetes big
Mouse model is randomly divided into 4 groups, every group 10 after three days according to rat blood sugar value.8d is administered in each group continuous gavage, one time a day, gives
Pharmaceutical quantities are 4.5mg allicins/kg, and 2h takes blood after last time is administered, and measure blood glucose value.
2nd, subjects：Tested SD rats are randomly divided into 4 groups, every group 10, tested SD rat primaries diet control and
Activity is constant, group 1 take black garlic muffin do, organize 2 take black garlic powder cake, group 3 takes black garlic powder seasoning packet, organizes and 4 takes black garlic
Pulverized sugar fruit.
3rd, experimental result
Different experiments group is hypoglycemic, and the results are shown in Table 9.
9 different experiments group blood sugar decreasing effect of table compares
Note：（1）The * P compared with blank group<0.01；（2）Compared with blank groupΔP<0.05
The animal test results of table 9 show high blood of the black garlic powder product of the present invention to Experimental Diabetes of Mice
Sugar is respectively provided with decline effect, shows that the black garlic powder product of the present invention is respectively provided with apparent antidiabetic function, has to diabetes
Significant auxiliary therapeutic action.
Embodiment 12：The zoopery of black garlic powder reducing blood lipid
According to the Ministry of Public Health《Health food is examined and assessment technique specification（2003）》Auxiliary lipid-lowering function animal it is real
Evaluation method is tested, embodiment 3 and 5~7 gained black garlic powder product of embodiment are evaluated, it is specific as follows：
1st, test material and method：
Wistar male rats 40,200 ± 20g of weight are provided by Wuhan University's Experimental Animal Center.It is high to induce rat
Blood fat disease pathological model formula（High lipid food）：1% cholesterol, 10% yolk are added in basal feed, 10% lard is dried into
Block.
The preparation method of Hyperlipemia model rat：Wistar male rats are randomly divided into 4 groups (every group 10), i.e., it is high
Blood fat rat（Hyperlipemia model control group）, feed high lipid food（High lipid food formula is basic feed 93.8%, cholesterol
1.0%th, lard 5.0%, cholate 0.2%）, do not give tested material；
Medication：
Tested Hyperlipemia model rat is randomly divided into 4 groups, every group 10, tested Hyperlipemia model rat original is drunk
Food control and activity it is constant, group 1 take black garlic muffin do, organize 2 take black garlic powder cake, group 3 take black garlic powder seasoning packet, organize 4
Take black garlic pulverized sugar fruit.
All animals raise 20d under identical environment, and dosage is 4.5mg allicins/kg.Last is given each tested
After the 4h of object, take hematometry serum total cholesterol (TC mmol/L, iron chloride development process), serum triacylglycerol (TG mmol/L,
Acetylacetone method), high-density lipoprotein cholesterol (HDL-C mmol/L, phosphotungstic acid method).
2nd, experimental result
The content of each group rat blood serum total TG, TC and HDL-C are shown in Table 10.
The effect of 10 different experiments group of table drop TC, TG, HDL-C compare
Note：（1）* P is represented<0.05；（2）* represents P<0.01
Table 10 the experimental results showed that：Compared with before test-meal, black garlic powder prepared by embodiment 3 and embodiment 5~7 is taken
The rat of product, Rat Cholesterol after test-meal 30d, triglyceride compared with there is apparent reduction before test-meal, high-density lipoprotein compared with
There is apparent raising before test-meal, black garlic powder product of the present invention has significant auxiliary therapeutic action to hyperlipidemia.
Embodiment 13：Black garlic powder is hypoglycemic, the experiment of the human experiment of reducing blood lipid
According to the Ministry of Public Health《Health food is examined and assessment technique specification（2003）》Auxiliary hyperglycemic, hypolipemic function
Human experiment experimental evaluation method evaluates embodiment 3 and 5~7 gained black garlic powder product of embodiment, specific as follows：
1st, human experiment and test method：
40 type II diabetes people, wherein 30 people of male, 10 people of women, the range of age 43~75 are selected by the principle of voluntariness
Year, without complication such as serious conscience kidneys, in taking before test-meal after contrast design.
Subject is randomly divided into 4 groups, every group of 10 people, subject's original medicine type, diet control and activity are not
Become, group 1 take black garlic muffin do, organize 2 take black garlic powder cake, group 3 takes black garlic powder seasoning packet, organizes and 4 takes black garlic pulverized sugar fruit,
Daily 1 time, in one after each meal, 30d is continuously taken, dosage is 0.5mg allicins/kg.
The variation of patient blood pressure, stool and urine, weight is monitored, and measures empty stomach and the blood glucose of postprandial 2h（It is glycoxidative with grape
Enzyme process）；Measure blood fat（T-CHOL TC, triglycerides TG and high-density lipoprotein HDL-C）.
2nd, judgment criteria：
It is effective：Cardinal symptom disappears, and declines on an empty stomach or before the relatively treatment of the blood glucose of postprandial 2h and is no more than 30.0%.
Effectively：Cardinal symptom is obviously improved, and declines before relatively being treated with the blood glucose of postprandial 2h on an empty stomach and is no more than 10.0%.
In vain：Cardinal symptom is not improved, and 10.0% is dropped by less than before relatively being treated with the blood glucose of postprandial 2h on an empty stomach.
3rd, human experiment result：
After test-meal 30d, the patient of each black garlic powder product, compared with before test-meal, the blood pressure of patient, stool and urine, weight are taken
Difference that there are no significant, but fasting blood-glucose, 2h-plasma glucose have apparent attenuating, and concrete outcome is shown in Table 11.
About the influence to the blood fat before and after test-meal：Take the patient of each black garlic powder product, compared with before test-meal, test-meal
Compared with there is apparent reduction before test-meal, high-density lipoprotein is apparent compared with having before test-meal for the cholesterol of patient, triglyceride after 30d
Raising, concrete outcome are shown in Table 12.
It can be seen that healthcare function of the black garlic powder product of the present invention with apparent auxiliary hyperglycemic, reducing blood lipid,
And to the harmless effect of tested population health.
Table 11 foretastes crowd's blood glucose test results
Table 12 foretastes crowd's lipids detection result
Note：（1）* P is represented<0.05；（2）* represents P<0.01
Embodiment 14：Black garlic powder antitumor animal is tested
According to the Ministry of Public Health《Health food is examined and assessment technique specification（2003）》Anti-tumor function human experiment it is real
Evaluation method is tested, embodiment 3 and 5~7 gained black garlic powder product of embodiment are evaluated, it is specific as follows：
1st, test material and method：
BALB/c mouse (4~6 week old, male, 20~24g of weight) 50, by the hepatoma cells of exponential phase
It is subcutaneous that MM45T.Li is seeded in the right armpit of BALB/c mouse, every inoculation 5 × 107A cell, establishes Transplanted tumor model.
Medication：
Tested rat model is randomly divided into 5 groups, every group 10, original diet control and activity are constant, and group 1 takes black garlic
Muffin, which does, organizes 2 takes black garlic powder cake, group 3 takes black garlic powder seasoning packet, group 4 takes black garlic pulverized sugar fruit, and group 5 takes physiology salt
Water, successive administration 30d, dosage are 4.5mg allicins/kg.It observes the pretherapy and post-treatment ordinary circumstance of mouse and tumor size becomes
Change.
1 tumour longest diameter (a) and shortest diameter (b) are measured per 2d with vernier caliper after into knurl, by formula TV=a × b2/2
Knurl approximate volumes (TV is obtained：Volume).Drug tumor-inhibiting action is evaluated by the following method：Animal is put to death in the 2d of last dose
Tumor weight is weighed, and as the following formula：
Calculate drug tumour inhibiting rate (IR)：Tumour growth tumour inhibiting rate=(control group average knurl weight-black garlic powder food group is averaged knurl
Weight)/control group average knurl weight × 100%.It is acted on inhibition rate of tumor growth IR evaluation Antitumor Activity of Drugs, therapeutic evaluation mark
It is accurate：IR ＜ 30 are invalid, and IR >=30 are effective.
As a result 13 be see the table below.
The effect of 13 different experiments group Tumor growth inhibition of table compares
Table 13 the experimental results showed that：Compared with the control group, the rat of the black garlic powder product of the present invention, test-meal 30d are taken
Drug tumour inhibiting rate has apparent reduction afterwards, shows that black garlic powder product of the present invention has significant auxiliary treatment to tumour
Effect.
In the description of this specification, reference term " one embodiment ", " example ", " is specifically shown " some embodiments "
The description of example " or " some examples " etc. means specific features, structure, material or the spy for combining the embodiment or example description
Point is contained at least one embodiment of the present invention or example.In the present specification, schematic expression of the above terms are not
Centainly refer to identical embodiment or example.Moreover, particular features, structures, materials, or characteristics described can be any
One or more embodiments or example in combine in an appropriate manner.
Although an embodiment of the present invention has been shown and described, it will be understood by those skilled in the art that：Not
In the case of being detached from the principle of the present invention and objective a variety of change, modification, replacement and modification can be carried out to these embodiments, this
The range of invention is limited by claim and its equivalent.
Claims (5)
1. the purposes of black garlic powder in medicine preparation, the drug is used to improve bacillus faecalis of dwelling in animal intestinal tract, Eubacterium, Ross
Visit the quantity of auspicious Salmonella, fecal bacteria, butyric acid vibrios, lactobacillus and galactococcus.
2. purposes according to claim 1, which is characterized in that the effective active composition of the black garlic powder is allicin, often
0.3~1.0mg allicins/kg is administered to the animal in day.
3. purposes according to claim 2, which is characterized in that daily to animal administration 0.5mg allicins/kg.
4. purposes according to claim 1, which is characterized in that the particle size of the black garlic powder is 60~150 μm.
5. purposes of the black garlic powder in food is prepared, the food is used to improve bacillus faecalis of dwelling in animal intestinal tract, Eubacterium, Ross
Visit the quantity of auspicious Salmonella, fecal bacteria, butyric acid vibrios, lactobacillus and galactococcus.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310391091.1A CN104415215B (en) | 2013-08-30 | 2013-08-30 | Purposes of the black garlic powder in microbial population of animal intestinal tract is adjusted |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310391091.1A CN104415215B (en) | 2013-08-30 | 2013-08-30 | Purposes of the black garlic powder in microbial population of animal intestinal tract is adjusted |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104415215A CN104415215A (en) | 2015-03-18 |
| CN104415215B true CN104415215B (en) | 2018-06-19 |
Family
ID=52966038
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310391091.1A Expired - Fee Related CN104415215B (en) | 2013-08-30 | 2013-08-30 | Purposes of the black garlic powder in microbial population of animal intestinal tract is adjusted |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104415215B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019126275A (en) * | 2018-01-23 | 2019-08-01 | 裕之 木元 | Health food |
| CN111202202A (en) * | 2020-03-11 | 2020-05-29 | 中国农业科学院农产品加工研究所 | Instant black garlic solid beverage and preparation method thereof |
| CN112293699A (en) * | 2020-11-02 | 2021-02-02 | 江苏福多美生物科技有限公司 | Production method of black garlic rich in amino acids |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19530455A1 (en) * | 1995-08-19 | 1997-02-20 | Gerd Winkler | Buttermilk drink with garlic flavour |
| CN102224908B (en) * | 2011-05-05 | 2013-01-30 | 中华全国供销合作总社济南果品研究院 | Preparation method of black garlic juice and black garlic powder |
| CN103169041A (en) * | 2011-12-21 | 2013-06-26 | 郑州固元堂医药科技有限公司 | Fermented black garlic powder production method |
-
2013
- 2013-08-30 CN CN201310391091.1A patent/CN104415215B/en not_active Expired - Fee Related
Non-Patent Citations (1)
| Title |
|---|
| Effect of garlic powder on the growth of commensal bacteria from the gastrointestinal tract;Angela Filocamo et al;《Phytomedicine》;20121231;第19卷;全文 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104415215A (en) | 2015-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Green et al. | Microbial medicine: prebiotic and probiotic functional foods to target obesity and metabolic syndrome | |
| KR100937455B1 (en) | Bowel movement promotion functional food containing psyllium seed, rice bran fermentation extracts and yeast extracts and manufacturing method thereof | |
| CN107951876A (en) | Purposes of the allicin in microbial population of animal intestinal tract is adjusted | |
| JP7011885B2 (en) | Composition that promotes intestinal health | |
| CN107752031A (en) | A kind of pulvis that there is regulation gut flora and protect gastric mucosa function and preparation method and application | |
| CN110433230A (en) | The therapeutical uses of Chardonnay seed products | |
| CN1980682A (en) | Flaxseeds for body weight management | |
| CN105211687A (en) | A kind of composition and method of making the same and purposes | |
| CN105079309B (en) | Composition for relaxing bowel | |
| CN106617080A (en) | Application of lentinan in preparation of healthcare food with intestinal flora regulating function | |
| CN115074298A (en) | Probiotic composition with effects of resisting claustrophobia, protecting stomach and promoting digestion and eliminating stagnation and application thereof | |
| CN104415215B (en) | Purposes of the black garlic powder in microbial population of animal intestinal tract is adjusted | |
| CN104413120A (en) | Black garlic and millet biscuit and preparation method thereof | |
| CN104661680B (en) | Compound and its influence to appetite control and insulin sensitivity | |
| CN104415214B (en) | Purposes of the black garlic extract in microbial population of animal intestinal tract is adjusted | |
| CN106465946A (en) | A kind of loosening bowel to relieve constipation dietary fiber | |
| US20110064833A1 (en) | Synergistic herbal composition and process of preparation thereof | |
| CN110122887A (en) | Improve the dietary fiber chewable tablets and preparation method thereof of gastrointestinal function | |
| CN113750149B (en) | Traditional Chinese medicine compound preparation for assisting in antioxidation | |
| US20230065964A1 (en) | Composition for enhancing urolithin production in a human subject | |
| Amalraj et al. | Efficacy and safety of a gut health product (Actbiome) prepared by incorporation of asafoetida-curcumin complex onto the turmeric dietary fiber in the management of gut health and intestinal microflora in healthy subjects: A randomized, double-blind, placebo controlled study | |
| WO2018132627A1 (en) | Dietary prebiotic supplement for promoting the activity of amylolytic and short-chain fatty acid producing microbes | |
| Dieny et al. | Body Mass Index is The Most Associated Anthropometry Indicators of Obesity with Insulin Resistance in Female College Students | |
| CN106619694A (en) | Uses of inulin and common yam rhizome polysaccharide composition in preparation of health food having intestinal flora regulating effect | |
| WO2019170790A1 (en) | Yeast beta glucans |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: 518083 11F-3, Beishan industrial complex, 146 Beishan Road, Yantian District, Shenzhen, Guangdong Applicant after: BGI SHENZHEN Co.,Ltd. Applicant after: Shenzhen Huada Sansheng Garden Technology Co.,Ltd. Address before: 518083 11F-3, Beishan industrial complex, 146 Beishan Road, Yantian District, Shenzhen, Guangdong Applicant before: BGI SHENZHEN Co.,Ltd. Applicant before: SHENZHEN BGI AGRICULTURE AND CYCLE ECONOMIC TECHNOLOGY Co.,Ltd. |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20180921 Address after: 518083 2 building, Beishan Industrial Zone, 146 Beishan Road, Yantian District, Shenzhen, Guangdong, China, 11 Co-patentee after: BGI PRECISION NUTRITION (SHENZHEN) TECHNOLOGY CO.,LTD. Patentee after: BGI SHENZHEN Co.,Ltd. Address before: 518083 11F-3, Beishan industrial complex, 146 Beishan Road, Yantian District, Shenzhen, Guangdong Co-patentee before: Shenzhen Huada Sansheng Garden Technology Co.,Ltd. Patentee before: BGI SHENZHEN Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20191225 Address after: 518120 A205, Peng Fei Road, Dapeng street, Dapeng New District, Shenzhen, Guangdong, China, 7 Co-patentee after: BGI PRECISION NUTRITION (SHENZHEN) TECHNOLOGY CO.,LTD. Patentee after: Shenzhen Huada Gene Agriculture Holding Co.,Ltd. Address before: 518083 2 building, Beishan Industrial Zone, 146 Beishan Road, Yantian District, Shenzhen, Guangdong, China, 11 Co-patentee before: BGI PRECISION NUTRITION (SHENZHEN) TECHNOLOGY CO.,LTD. Patentee before: BGI SHENZHEN Co.,Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20180619 |